Improving Outcomes with First-Line Endocrine-Based Therapy for Patients with HR-Positive, HER2-Negative Metastatic Breast Cancer
Breast Cancer Update
00:00
CDK Inhibitors in Elderly Breast Cancer Patients
This chapter explores the use of CDK inhibitors, particularly palbocyclib and ribocyclib, in treating older patients with HR-positive, HER2-negative metastatic breast cancer. It discusses their tolerability, survival benefits, and an upcoming study aimed at optimizing treatment strategies for this demographic.
Play episode from 08:00
Transcript
